Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease

International Journal of Molecular Sciences

Nicholas J. Geraghty¹  Katrina M. Bird¹  Ronald Sluyter¹  Sam R. Adhikary¹  Debbie Watson¹  Peter Cuthbertson¹  Stephen J. Fuller² 

[1] Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia;Sydney Medical School Nepean, University of Sydney, Nepean Hospital, Penrith, NSW 2747, Australia;

关键词: P2X7 receptor;    P2Y receptor;    adenosine receptor;    CD39;    CD73;    ATP;   

DOI  :  10.3390/ijms22158343

来源: DOAJ

【 摘 要 】

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for blood cancers and other haematological disorders. However, allo-HSCT leads to graft-versus-host disease (GVHD), a severe and often lethal immunological response, in the majority of transplant recipients. Current therapies for GVHD are limited and often reduce the effectiveness of allo-HSCT. Therefore, pro- and anti-inflammatory factors contributing to disease need to be explored in order to identify new treatment targets. Purinergic signalling plays important roles in haematopoiesis, inflammation and immunity, and recent evidence suggests that it can also affect haematopoietic stem cell transplantation and GVHD development. This review provides a detailed assessment of the emerging roles of purinergic receptors, most notably P2X7, P2Y₂ and A_2A receptors, and ectoenzymes, CD39 and CD73, in GVHD.

【 授权许可】

Unknown